Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 339-346

  Mesquita, Maria ^a   Demulder, Anne ^a   Damry, Nasroolla ^a   Mélot, Christian ^b   Wittersheim, Eric ^a   Willems, Dominique ^a   Dratwa, Max ^a   Bergmann, Pierre ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Arteriosclerosis; Cardiovascular disease; Chronic kidney disease; Hemodialysis; Osteoprotegerin (OPG); Vascular calcification

Indexed keywords

OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY VASCULAR CALCIFICATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL RATE;

EID: 63849210529     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.075     Document Type: Article

References (33)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S16-23.
2. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-9.
3. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on longterm hemodialysis. Am J Kidney Dis 2003;42:303-9.
4. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft F. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
5. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-64.
6. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int 2005; 94(Suppl 94):S120-7.
7. Sundeep K. Minireview: the OPG/RANK-L/RANK system. Endocrinology 2001;142:5050-5.
8. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev 1998;12:1260-8.
9. Hopbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANK-L/RANK system for bone and vascular diseases. J Am Med Assoc 2004;292:490-5.
10. Jono S, Ikary Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
11. Schoppet M, Sattler AM, Schaeffer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024-8.
12. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28:2176-80.
13. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44:1970-6.
14. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39: 525-32.
15. Wittersheim E, Mesquita M, Demulder A, Guns M, Louis O, Melot C, et al. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin Biochem 2006;39:617-22.
16. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002;40:1019-23.
17. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-70.
18. Hjelmesth J, Ueland T, Flyvbjerg A, Flyvbjerg A, Bollerslev J, Leivestad T, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006;17:1746-54.
19. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, et al. Receptor activator of nuclear factor kappa and osteoprotegerin regulate aortic valve calcification. J Mol Cardiol 2004;36:57-66.
20. Dovio A, Generali D, Tampellini M, Berruti A, Tedoldi S, Torta M, et al. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANK: a rhythmometric analysis. Osteoporos Int 2008;19:113-7.
21. Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, et al. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. J Clin Endocrinol Metab 2007;92:3230-8.
22. Chen D, Sarikaya NA, Gunn H, Martin SW, Young JD. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin Chem 2001;47:747-9.
23. Halliburton SS, Stilman AE, White RD. Noninvasive quantification of coronary artery calcification: methodsand prognostic value. Cleve Clin Med 2002;69(Suppl 3):S6-11.
24. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
25. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-21.
26. Matsuoka M, Ieki K, Tamashiro M, Fujimoto N, Higa N, Touma T, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8:54-8.
27. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from Dallas Heart Study). Am J Cardiol 2007;99:513-8.
28. Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534-9.
29. Mazzafero S, Pasquali M, Pugliese F, Barresi G, Carbone I, Francone M. Serum levels of calcification inhibition proteins and coronary artery calcium score: comparisonbetween transplantation and dialysis. Am J Nephrol 2007;27:75-83.
30. Avbersek-Luznik I, Balon B, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 2005;20: 566-70.
31. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002;17:233-8.
32. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Austrian study group on normative values of bone metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-6.
33. Brower WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.